Tocilizumab had the ability to significantly increase hemoglobin, carbon dioxide, MCV, and RDW levels and decrease blood D-dimer, AST, and CRP concentrations, which is different from what was reported by other studies that assessed the effect of tocilizumab in rheumatoid arthritis patients and reported an increase in blood hemoglobin level [45,46]. Here, CRP is linked to rheumatoid arthritis.